Acutus secures FDA clearance for new real-time heart mapping algorithm

EKG rhythm
The SuperMap algorithm is designed to help physicians map the heart’s chambers, perform an ablation, and then quickly re-map to confirm the effects. (Pixabay)

Acutus Medical has secured an FDA green light for a heart mapping algorithm designed for its AcQMap 3D imaging system.

The former Fierce 15 winner’s new SuperMap program was cleared to help guide electrophysiologists in the diagnosis and treatment of stable and transient arrhythmias, by providing high-resolution, whole-chamber maps of the heart’s left or right atria.

According to Acutus, the SuperMap software addition visualizes atrial rhythms in under three minutes, through a roving, non-contact approach the company describes as “hover-mapping.”

This allows physicians to map the heart’s chambers, perform an ablation, and then quickly re-map the atria to confirm the effects—while also identifying regions of slow electrical conduction or irregular activity, as well as focal points.

The AcQMap system previously offered both contact and non-contact mapping, and received a CE Mark for use of the SuperMap algorithm in October 2019.

“With three distinct and unique mapping modalities in one system, physicians can feel confident in tackling any atrial arrhythmia accurately and efficiently,” Acutus President and CEO Vince Burgess said in a statement.

RELATED: Acutus Medical raises $170M to push it further into arrhythmia treatment

In May of last year, Acutus announced it would move deeper into arrhythmia treatments, expanding its portfolio beyond heart mapping and visualization with the acquisition of catheter developer Rhythm Xience.

At the same time, the company announced team-ups with Peerbridge Health, Cardiac Designs and MedFact, to provide electrocardiogram support, patient monitoring and radiofrequency ablation, respectively.

Shortly after that, Acutus raised $170 million—including a $100 million series D round plus $70 million in credit from Deerfield Management and OrbiMed—to be put towards its global business development and commercialization endeavors.

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.